We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A qui tam lawsuit, unsealed Tuesday, alleges that Takeda used a sham clinical trial to obtain FDA approval for a new version of its gout drug Colcrys — raking in hundreds of millions of dollars as a result and delaying generic competition.